Cutler Group LLC / CA - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 180 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.

Quarter-by-quarter ownership
Cutler Group LLC / CA ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$57
-34.5%
4,200
-25.0%
0.01%
-50.0%
Q2 2023$87
+112.2%
5,600
+93.1%
0.01%
+140.0%
Q1 2023$41
+2.5%
2,900
-71.7%
0.01%
+66.7%
Q4 2022$40
-99.9%
10,233
-0.9%
0.00%
-25.0%
Q3 2022$45,000
-81.9%
10,323
-75.4%
0.00%
-77.8%
Q2 2022$248,000
+74.6%
42,000
+371.9%
0.02%
+125.0%
Q1 2022$142,000
-54.0%
8,900
-44.7%
0.01%
-38.5%
Q4 2021$309,000
-50.6%
16,100
-56.5%
0.01%
-53.6%
Q3 2021$626,000
+198.1%
37,000
+487.3%
0.03%
+180.0%
Q2 2021$210,0006,3000.01%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q4 2021
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders